Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized double-blind placebo-controlled single and multiple ascending dose study of ANXV in healthy male subjects
NL-OMON51171Phase 1Active, not recruiting
- Sponsor
- Annexin Pharmaceuticals AB
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Vein occlusion (RVO) comparing ANXV with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Dec 2020; status: active, not recruiting.
02
Drugs
annexin a5
03
Conditions
Vein occlusion (RVO)
Beyond the preview
Go deeper on NL-OMON51171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51171.